Actinium Pharmaceuticals, Inc.
ATNM · AMEX
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $0 | $0 | $0 | $0 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | -$0 | $0 | $0 | $0 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | -100% | -92.1% | -10% | – |
| Gross Profit | -$0 | $0 | $0 | $0 |
| % Margin | – | 100% | 100% | 54.2% |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | – | -63,123.5% | -3,243.2% | -2,119.8% |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | – | -60,269.1% | -3,205.5% | -2,165.6% |
| EPS Diluted | -1.27 | -1.83 | -1.37 | -1.2 |
| % Growth | 30.6% | -33.6% | -14.2% | – |
| Operating Cash Flow | -$0 | -$0 | $0 | -$0 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$0 | -$0 | $0 | -$0 |